-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Checkpoint Therapeutics to Neutral, Announces $4.1 Price Target

Benzinga·03/11/2025 10:39:26
Listen to the news
HC Wainwright & Co. analyst Joseph Pantginis downgrades Checkpoint Therapeutics (NASDAQ:CKPT) from Buy to Neutral and announces $4.1 price target.